ProShares Ultra Nasdaq Biotechnology
 
 
 
 
基本資料
種類: ETF
費用比率%: 0.95
資產淨值: 83.97
成立日期: 06/04/2010
 
分析
市值分佈:
53.76%
大市值
6.31%
中市值
2.60%
小市值
持股比例加總可能不達100%,原因包括ETF持有現金或衍生工具。
 
 
行業分佈 國家/地區分佈
 
投資組合
 (更新時間: 07/03/2026 05:58) 總持有投資項目: 248  
0%
 
100%
     10大 (31.38%)
代號 名稱 佔比% 持有日期
ACLXArcellx0.3327/02/2026
KYMRKymera Therapeutics0.3327/02/2026
RYTMRhythm Pharmaceuticals0.3127/02/2026
COGTCogent Biosciences0.3027/02/2026
PTGXProtagonist Therapeutics0.2927/02/2026
CRSPCRISPR Therapeutics AG0.2927/02/2026
CAICaris Life Sciences Inc0.2927/02/2026
ALKSAlkermes plc0.2527/02/2026
IMVTImmunovant0.2427/02/2026
CGONCG Oncology0.2427/02/2026
MIRMMirum Pharmaceuticals0.2427/02/2026
SRRKScholar Rock Holding Corp0.2327/02/2026
AMRXAmneal Pharmaceuticals0.2227/02/2026
GPCRStructure Therapeutics0.2127/02/2026
ACADACADIA Pharmaceuticals0.2127/02/2026
INDVIndivior Pharmaceuticals Inc.0.2127/02/2026
NAMSNewAmsterdam Pharma Company NV0.2027/02/2026
LGNDLigand Pharmaceuticals0.2027/02/2026
CRNXCrinetics Pharmaceuticals0.2027/02/2026
ERASErasca0.2027/02/2026
  1    2   3    4    5    6    7    8    9    10    11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.